iiinova — where your digital self keeps evolving

Reposted by Johannes Levin

Mind, Brain and Behavior Research Center - CIMCYC @cimcyc.bsky.social · 06/11/2025

During the session, renowned experts—including Prof. @johanneslevin.bsky.social (LMU), Prof. Jason Hassenstab @ctrlab.org and Prof. Andre Strydom (King's College London)—reviewed the latest scientific advances in the field.

111

Johannes Levin @johanneslevin.bsky.social · 30/08/2025

Alzheimer ist die häufigste Todesursache bei Menschen mit Down-Syndrom. Die Alzheimer Forschung Initiative hat hierzu ein neues Video veröffentlicht. Wir freuen uns sehr, dass die spezialisierte Ambulanz an der Neurologie der LMU München erwähnt wird. 👉 Zum Video: youtu.be/UovdbwD44F0?...

120

Johannes Levin @johanneslevin.bsky.social · 07/06/2025

It was a great honor to host the #GENFI summer meeting 2025. Two days of excellent talks and inspiring discussions. Thanks for coming to Munich and safe travels to everyone.

070

Johannes Levin @johanneslevin.bsky.social · 28/05/2025

¡¡Día histórico para el Betis!! ¿Cómo va a quedar esto? ¡Vamos con todooo! 💚⚽️ What a historic day for Betis!! How’s this gonna end? Let’s gooo! 💚⚽️

030

Johannes Levin @johanneslevin.bsky.social · 30/03/2025

TOPAS-MSA is launching in Japan. The investigator meeting took place yesterday and today in Yokohama. Japan’s strong tradition in MSA research and the outstanding dedication of the trial sites created an exciting environment. We’re thrilled to have you on board. clinicaltrials.gov/study/NCT065...

041

Johannes Levin @johanneslevin.bsky.social · 21/02/2025

We did it and now it is published: A highly Lewy-fold selective and quantitative Synuclein Aggregate Amplification Assay (SAA). Huge thanks to the amazing teams at MODAG GmbH, LMU Munich, and Bologna University! rdcu.be/eaISM

rdcu.be

A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease

084

Johannes Levin @johanneslevin.bsky.social · 12/02/2025

The TOPAS-MSA study investigating emrusolmin for disease modification in Multiple System Atrophy (MSA) is starting in Europe. Impressions from the investigator meeting in Barcelona (Spain). www.clinicaltrials.eu/trial/study-of-emrusolmin-for-treating-adults-with-multiple-system-atrophy/

Group foto with our wonderful team from TEVA and MODAG.

020

Johannes Levin @johanneslevin.bsky.social · 06/01/2025

So well deserved. An example to follow for all of us.

010

Reposted by Johannes Levin

Scott Berry @statberry.bsky.social · 01/12/2024

Still on my 25-year crusade to end all two-sided alpha testing in superiority trials. It's something simulating clinical trials brings out as just plain silly.

2143

Reposted by Johannes Levin

Jason Hassenstab @ctrlab.org · 17/12/2024

A interesting body of commentary from key people on this critically important topic. Definitely worth a read. Is removing substantial amyloid plus meeting safety targets enough to approve a treatment for #Alzheimer's? #ENDALZ www.alzforum.org/news/researc...

alzforum.org

Is It Time to Approve Drugs Based on Amyloid Removal? | ALZFORUM

284

Reposted by Johannes Levin

Jon Lim, FRCP PhD @drjonlim.bsky.social · 23/11/2024

🎨 In case anyone need… The NIH BioArt Source is an awesome library of *free* professionally drawn illustrations for scientific presentations or figures. Downloadable in HD. Thank you NIH for this invaluable tool 🙏! Check it out 👇 bioart.niaid.nih.gov

441197491

Reposted by Johannes Levin

Jason Hassenstab @ctrlab.org · 18/11/2024

Day two on @bsky.app and I'll go ahead say I'm LOVING IT. Fellow #scientists and #Alzheimer's and #ADRD peeps: Tell everyone you know to get on over here! The skies are blue once again!

media.tenor.com

a man in a suit and tie is sitting at a desk and saying `` i love it '' .

ALT: a man in a suit and tie is sitting at a desk and saying `` i love it '' .

2273